|
| |
Northwest BiotherapeuticsNorthwest Biotherapeutics (NWBT) is a biotechnology company focused on the clinical development of autologous immunotherapy products for cancer. Our technology platform, DCVax®, uses a patient’s own dendritic cells, the starter engine of the immune system, which are loaded with tumor proteins or antigens. Injection of these cells back into the patient initiates a potent immune response against cancer cells, resulting in delayed time to progression and prolonged survival. Our two lead product candidates, DCVax®-Prostate and DCVax®-Brain are entering FDA-allowed late stage clinical trials from which licensure is possible. Other, related products in our pipeline are ready to enter Phase I clinical trials. The advantage of our DCVax® platform is derived from:
the high quality and purity of our DCVax® product candidates;
our unique therapeutic approach in which immunotherapy is positioned as an adjuvant treatment in patients with low tumor burden;
our proprietary, efficient, and low cost method of product manufacturing.
| Contact Details: |
| 18701 120TH AVENUE NE, SUITE 101 |
| Bothell |
| Washington |
| 98011 |
| United States of America |
| Tel: | 425-608-3000 |
| Fax: | |
| Email: | info@nwbio.com |
| WWW: | www.nwbio.com/
|
|
Loading...
|
Recent Publications by Northwest Biotherapeutics: |  |
Validation of the COSTIM bioassay for dendritic cell potency.
Dendritic cells (DCs) are increasingly prepared in vitro for use in... | 29th April, 2005
| Northwest Biotherapeutics, Inc., 22322, 20th Avenue SE, Bothell, WA 98021,
| J Pharm Biomed Anal. 2004 Oct 29;36(2):285-94.
DOI Direct Link |
The COSTIM bioassay: a novel potency test for dendritic cells.
The utility of dendritic cells (DCs) in experimental immunotherapy has... | 16th April, 2004
| Northwest Biotherapeutics, Inc., 22322-20th Avenue S.E., Bothell, WA
| J Immunol Methods. 2004 Feb 15;285(2):293-9.
DOI Direct Link |
Interferon-gamma Added During Bacillus Calmette-Guerin Induced Dendritic Cell Maturation Stimulates Potent Th1 Immune Responses.
Dendritic cells (DC) are increasingly prepared in vitro for use in... | 29th October, 2003
| Northwest Biotherapeutics, Inc, 21720-23rd Dr, SE, Suite 100, Bothell, WA,
| J Transl Med. 2003 Oct 10;1(1):7.
DOI Direct Link |
Dendritic cells efficiently acquire and present antigen derived from lung cancer cells and induce antigen-specific T-cell responses.
Active immunotherapy of cancer requires the availability of a source of... | 26th August, 2003
| Vaccine Research and Development Division, Northwest Biotherapeutics Inc.,
| Cancer Immunol Immunother. 2003 Jul;52(7):413-22. Epub 2003 Feb 15.
DOI Direct Link |
Immune monitoring: it's prudent to adopt current quality regulations.
The United States Food and Drug Administration and its international... | 23rd May, 2003
| Quality Control and Immune Monitoring, Northwest Biotherapeutics, Inc.,
| Trends Biotechnol. 2002 Dec;20(12):495-7.
|
→View more Northwest Biotherapeutics research publications. |
Press Releases on Northwest Biotherapeutics:
|
 |
| Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment |
26th October, 2009 |
Reportlinker |
-- A focus on "engineered" antibodies
Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment reviews the broad drug development effort that is focused on bringing
|
| Long-Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax(R)-Brain |
21st October, 2009 |
Northwest Biotherapeutics, Inc. |
BETHESDA, M.D., Oct. 21 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ("NWBT" or the "Company") (OTC Bulletin Board: NWBO) today announced further long-term follow-up
|
| Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action |
8th January, 2009 |
Northwest Biotherapeutics, Inc. |
BETHESDA, Md., Jan. 8 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBO; AIM: NWBS and NWBT) (the "Company" or "NWBT") announced today settlement
|
| Northwest Secures US$0.5 Million Debt Financing |
23rd December, 2008 |
Northwest Biotherapeutics, Inc. |
BETHESDA, Md., Dec. 23 /PRNewswire-FirstCall/ -- Northwest
Biotherapeutics, Inc. (OTC Bulletin Board: NWBO; AIM: NWBS and NWBT), today
announced that it has obtained US$0.5 million in debt funding
|
| Northwest Biotherapeutics Reports Encouraging Data on First Patients Who Have Completed Its Phase I/II Clinical Trial of DCVax(R)-L in Metastatic Ovarian Cancer |
23rd December, 2008 |
Northwest Biotherapeutics, Inc. |
BETHESDA, Md., Dec. 23 /PRNewswire-FirstCall/ --
(OTC Bulletin Board: NWBO; AIM: NWBT and NWBS) Northwest Biotherapeutics, Inc.
("NWBT") today announced encouraging data on clinical
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 378 times since April 2007, the link to the organisation's website has been followed 77 times Recent Search Terms used to find this page: drug discovery biotherapeutics aim focus | AIM NWBS | Northwest Biotherapeutics patent | . Search for more companies in Bothell Search for more companies in Washington This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Northwest Biotherapeutics |
